01—Abstract
Summary
Summary of the 8-K filed August 19, 2025. Cited figures are marked; the original filing is the authoritative source.
Medtronic reported first quarter fiscal 2026 results (quarter ended July 25, 2025) showing revenue of $8.578 billiona, up 8.4% as reported and 4.8% organic, marking the 11th consecutive quarter of mid-single-digit organic growth.
GAAP diluted EPS was $0.81b (up 1%) and non-GAAP diluted EPS was $1.26 (up 2%). Cardiac Ablation Solutions revenue grew nearly 50%, driven by pulsed field ablation, while Diabetes grew 7.9% organic. Management reiterated FY26 organic revenue growth guidance of approximately 5% and raised non-GAAP diluted EPS guidance to $5.60-$5.66 from $5.50-$5.60, reflecting a lower expected tariff impact of about $185 million.
Non-GAAP operating margin declined 80 basis points to 23.6%, and free cash flow was $584 millionc versus $466 million a year earlier. The filing also discloses governance changes. The Board expanded from 11 to 13 directors, adding John Groetelaars and William Jellison, and formed two new committees, a Growth Committee and an Operating Committee, both chaired by CEO Geoff Martha.
The company framed these steps as following constructive dialogue with activist investor Elliott Management, which the press release describes as having become one of Medtronic's largest investors. Medtronic also plans an Investor Day in mid-2026 and continues the planned separation of its Diabetes business (MiniMed).
For investors, the key takeaways are the EPS guidance raise and the growth momentum in cardiac ablation, balanced against a slight margin decline and continued reliance on second-half acceleration to meet growth targets. The Elliott involvement and new committees signal heightened focus on portfolio simplification, margin improvement, and capital allocation.
02—Key points
Key Highlights
- Q1 FY26 revenue of $8.578B, up 8.4% reported and 4.8% organic, the 11th straight quarter of mid-single-digit organic growth
- Non-GAAP diluted EPS of $1.26 (up 2%); GAAP diluted EPS of $0.81 (up 1%)
- FY26 non-GAAP diluted EPS guidance raised to $5.60-$5.66 from $5.50-$5.60; FY26 organic revenue growth guidance of ~5% reiterated
- Cardiac Ablation Solutions revenue rose nearly 50% (72% in the US), led by pulsed field ablation
- Non-GAAP operating margin fell 80 bps to 23.6%, while free cash flow rose to $584M from $466M
- Board expanded to 13 members with John Groetelaars and William Jellison appointed; new Growth and Operating Committees formed, chaired by CEO Geoff Martha
- Governance changes follow constructive engagement with Elliott Management, which became one of Medtronic's largest investors; Investor Day planned for mid-2026
03—Questions
Frequently Asked Questions
Did Medtronic change its earnings guidance?
Yes, partially. The company raised FY26 non-GAAP diluted EPS guidance to $5.60-$5.66 from $5.50-$5.60, citing Q1 outperformance and a reduced expected tariff impact of about $185 million (previously $200-$350 million). It reiterated FY26 organic revenue growth guidance of approximately 5%.
What drove Medtronic's revenue growth in the quarter?
Growth was led by Cardiovascular, up 7.0% organic, with Cardiac Rhythm & Heart Failure up 9.1% organic and Cardiac Ablation Solutions up nearly 50%. Neuroscience grew 3.1% organic, Medical Surgical grew 2.4%, and Diabetes grew 7.9%.
Why did the Board add new directors and create new committees?
The Board said the moves sharpen governance around strategic portfolio management, operational execution, and capital allocation. The Growth Committee will oversee tuck-in M&A, R&D investment, potential divestitures, and the Diabetes separation. The Operating Committee will oversee margin expansion and manufacturing and supply chain efficiency. The announcements followed dialogue with Elliott Management.
Is the Diabetes business being separated?
Yes. The press release references the recently announced plan to separate the Diabetes business (MiniMed), and the Growth Committee will oversee its continued execution. The filing also notes separation-related exit-of-business charges in the quarter.
Are margins and profitability improving?
Mixed. GAAP operating margin rose 70 bps to 16.8%, but non-GAAP operating margin declined 80 bps to 23.6%, and non-GAAP operating profit rose only 3%. Management expects earnings acceleration from manufacturing, supply chain, and operating expense efficiencies, though it is also increasing R&D and sales and marketing investment.
04—Continue